✦ LIBER ✦

Comparison Between Everolimus (Afinitor®) and Chemotherapy Agents (Capecitabine, Docetaxel and Doxorubicin) for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2–) Advanced or Metastatic Breast Cancer

✍ Scribed by Vieira, J.; Chandiwana, D.; Taylor, M.; Lewis, L.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An Indirect Treatment Comparison of the

✍ Chandiwana, D.; Vieira, J.; Granville, J.; McCool, R.; Fleetwood, K. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

PCN98 Health Outcome Gains and Costs Off

✍ M. Taylor; L. Lewis; J. Vieira; J.F. Ricci; D. Chandiwana; S. Saletan; T. Sahmou 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

Systematic review of lapatinib in combin

✍ Riemsma, Rob; Forbes, Carol A.; Amonkar, Mayur M.; Lykopoulos, Konstantinos; Dia 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 385 KB

Costs of HER 2 Negative, Hormonal Recept

✍ Clark, O.A.C.; Paladini, L.; Engel, T.; Caldas, A.; Valentim, J. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB